Progesterone Receptor Negative Recruiting Phase 2 Trials for Enobosarm (DB12078)

IndicationStatusPhase
DBCOND0038639 (Progesterone Receptor Negative)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02971761Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast CancerTreatment